23andMe launches GLP‑1 tool
23andMe is translating its research into a consumer-facing product: the company published findings on genetic predictors of GLP‑1 efficacy and side effects and rolled out a new GLP‑1 report plus an interactive tool through 23andMe Total Health. That means customers may soon be able to see whether their genetics suggest higher benefit or greater risk of nausea on drugs like semaglutide or tirzepatide — a step toward making obesity treatment more personalized. (biospace.com) (news-medical.net).
These drugs work by copying gut hormones that tell your brain you are full and tell your stomach to empty more slowly, which is why people on semaglutide and tirzepatide often eat less than they used to. A recent New England Journal of Medicine review says those effects come from reduced gastric emptying and stronger satiety signaling in the brain. (nejm.org) The slowdown in digestion is also why nausea shows up so often. The United States Food and Drug Administration label for Wegovy, the semaglutide obesity drug, lists nausea among the most common side effects at rates of 5% or higher. (accessdata.fda.gov) Doctors have known for years that one person can lose more than 20% of body weight on these drugs while another loses less than 5%, but they have not had a clean way to predict who lands where before treatment starts. 23andMe’s new study went looking for that answer in human DNA. (mediacenter.23andme.com) The company analyzed 27,885 people who reported using glucagon-like peptide-1 drugs and ran what researchers call a genome-wide association study, which is basically a giant pattern search across the genome to see which letter changes travel with a trait. In this case, the traits were weight loss and side effects such as nausea and vomiting. (nature.com) One gene that stood out was GLP1R, which is the instruction manual for the receptor these drugs are built to hit like a key fitting a lock. A variant in that gene was linked to an extra 0.76 kilograms of weight loss for each copy of the effect allele. (nature.com) Another signal showed up in GIPR, which is the gene for a second gut-hormone receptor involved in appetite and digestion. 23andMe said variants there were associated with nausea and vomiting, pointing to a genetic clue for why some patients feel sick while others tolerate treatment better. (news-medical.net) 23andMe did not leave the finding inside a journal article. On April 8, 2026, it said it had added a “GLP-1 Medications: Weight Loss and Nausea” report and an interactive tool to its Total Health service, which the company says includes clinician guidance and clinician-reviewed reports. (mediacenter.23andme.com) That means the pitch is no longer just ancestry or raw genetic risk. The new product tries to answer a much more immediate question for someone considering obesity treatment: if two people take the same weekly shot, whose genes suggest more weight loss and whose genes suggest more nausea. (statnews.com) There is still a big limit here: the study found statistical links, not a guarantee for any one patient. Weight, dose, other illnesses, and how long someone stays on treatment still shape outcomes, so a genetic report is closer to a weather forecast than a yes-or-no test. (nature.com)
